AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02446067 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
Study NCT03393923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the anterior wedge
Description: Application of anterior wedge in tennis
Study NCT00913861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard sedation
Description: Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
Study NCT03440229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emulsifier-containing diet
Description: CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
Study NCT04468295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: measurement
Description: Assessment the rate of retraction for 6 months
Study NCT00793962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation radiotherapy
Description: radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
Study NCT00793962 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionation radiotherapy
Description: 50Gy/25/f/5w
Study NCT03769441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Four intravenous dosages of ferric(III) carboxymaltose
Study NCT03769441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Four intravenous dosages of sodiumchloride
Study NCT03175536 — intervention group
Intervention type: OTHER
Intervention: HDHP with PDL
Description: Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of >$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
Study NCT04115319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP363856
Description: SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
Study NCT04115319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine XR
Description: quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
Study NCT00677521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
Study NCT00913861 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured attention
Description: Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
Study NCT01622257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavitation US
Description: The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm\^2 adjustable, 60W with 20cm\^2 active surface).
Study NCT01622257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
Study NCT01622257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cavitation US + Metformin
Description: Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
Study NCT00497068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tobacco abstinent contingent
Description: Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
Study NCT00497068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-contingent
Description: Participants receive vouchers regardless of tobacco use status
Study NCT00497068 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control
Description: this group receives no vouchers
Study NCT03446716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Child attempted to go to bed 90 mins in advance of their normal bedtime.
Study NCT01325896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEG-Intron sc injection
Description: This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse.
Study NCT01393548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brompheniramine + phenylephrine
Description: Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient.
Study NCT04802486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXCAP©®
Description: EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
Study NCT01352195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forever Free Booklets
Description: Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
Study NCT03808649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1500ml of 2.5% mannitol
Description: 1500ml of 2.5% mannitol was used in experimental group
Study NCT03808649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500ml of 2.5% mannitol
Description: 1500ml of 2.5% mannitol was used in experimental group
Study NCT03808649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: different volume of 2.5% mannitol
Description: different volume of 2.5% mannitol based on BMI was used in active comparator group
Study NCT03059017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol Sulphate
Description: salbutamol sulphate packaged as aerosol
Study NCT03059017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niosomes
Description: Niosomes
Study NCT00861640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Omeprazole
Description: Intravenous Omeprazole 1amp qd (every day)
Study NCT00861640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Rabeprazole
Description: Oral Rabeprazole 1 bid
Study NCT01393548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brompheniramine + pseudoephedrine
Description: Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
Study NCT03053752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
Study NCT00365794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical testosterone gel 10 g/day
Description: Testosterone gel therapy for 20 weeks
Study NCT03618693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
Study NCT03618693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
Study NCT03618693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
Study NCT05134805 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar hemiarthroplasty , proximal femoral nail
Description: * Removal of head of femur , greater trochanter , and lesser trochanter and use bioplar hemiarthroplasty (BHA).~* Intra-medullary fixation of intertrchanteric femoral fracture by proximal femoral nail (PFN) Fixation of the fracture by using intramedullary nail(proximal femoral nail).
Study NCT04120896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Karate group
Description: Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
Study NCT04120896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kung fu group
Description: Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
Study NCT00009737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 425mg/m2 iv daily from day 1 to day 5 every 28 days.
Study NCT00009737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 20mg/m2 iv daily from day 1 to day 5 every 28 days.
Study NCT00009737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine [Xeloda]
Description: 1250mg/m2 po bid on days 1-14 every 21 days.
Study NCT01785043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
Study NCT01785043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
Study NCT01176578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training, 3 days per week
Study NCT01176578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 6 months of aerobic exercise training, 3 days per week
Study NCT03049371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention for both groups
Description: No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
Study NCT01093716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid® (rTMS)
Description: Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
Study NCT01696227 — intervention group
Intervention type: DRUG
Intervention: Nissle 1917
Description: Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
Study NCT02192541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
Study NCT02192541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
Study NCT04193033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLOW intervention
Description: The FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
Study NCT03023007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loco-regional anaesthesia
Description: Loco-regional anaesthesia
Study NCT03371680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 1-13 Carbon Leucine and deuterated water
Description: All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
Study NCT01695837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6
Study NCT01695837 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6
Study NCT01480882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy (CCPT)
Description: Conventional chest percussion will be applied for a duration of 15 minutes.
Study NCT01807585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaSeal SCS
Description: Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
Study NCT01807585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFast Radiofrequency Ablation (RFA)
Description: Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
Study NCT01874717 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: midazolam
Study NCT01874717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study NCT00244751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI262570 0.5 mg
Description: GI262570 0.5 mg
Study NCT01901640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8159 (Udenafil)
Study NCT05643014 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: This study will involve three sample collections including buccal cells and urine samples
Study NCT04259164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
Study NCT04259164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QMF149
Description: Mometasone / Indacaterol
Study NCT01480882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical percussion (LEGA)
Description: Mechanical chest percussion will be delivered by a device for 15 minutes.
Study NCT02681861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6294 Intravenous
Description: Intravenous (IV)
Study NCT02681861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6294 Subcutaneous
Description: Subcutaneous (SC)
Study NCT02681861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Intravenous
Description: Intravenous (IV)
Study NCT02681861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Subcutaneous
Description: Subcutaneous (SC)
Study NCT03982511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCIT-Health
Description: PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
Study NCT01991743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2.5
Description: Administration of bupivacaine 2.5 mg.
Study NCT01991743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 5
Description: Administration of 5 mg bupivacaine
Study NCT01991743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 7.5
Description: Administration of 7.5 mg bupivacaine
Study NCT01991743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 10
Description: Administration of 10mg bupivacaine.
Study NCT05479786 — intervention group
Intervention type: OTHER
Intervention: Expectant management
Description: Follow-up with beta-HCG dosages and transvaginal ultrasound scans
Study NCT05479786 — intervention group
Intervention type: PROCEDURE
Intervention: Salpingectomy
Description: Removal of the affected Fallopian tube by laparoscopy
Study NCT05479786 — intervention group
Intervention type: PROCEDURE
Intervention: Salpingostomy
Description: Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
Study NCT03692286 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Silver nanoparticle/Calcium hydroxide
Description: Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
Study NCT03692286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nanoparticles in gel form
Description: Intracanal medication composed of silver nanoparticles in gel form
Study NCT01807585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roll-in (VenaSeal SCS)
Description: Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
Study NCT03272100 — intervention group
Intervention type: PROCEDURE
Intervention: flap
Description: after flap incision , the sinus cavity was opened and then the membrane raised up
Study NCT01394861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESD using Master Slave Robotic System
Description: Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
Study NCT00244751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI262570 1.0 mg
Description: GI262570 1.0 mg
Study NCT00244751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03651271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab Monotherapy
Description: Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
Study NCT03651271 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab and Combination for Metastatic Cancer
Description: For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.